High Risk of Venous Thrombosis Recurrence in Fully Anticoagulated Patient with Antithrombin Deficiency during COVID-19: A Case Report

Indian Journal of Cardiovascular Disease in Women WINCARS

article

Mirjana Kovac¹  Olivera Markovic³  Sanja Lalic-Cosic⁴  Gorana Mitic⁵ 

[1] Faculty of Medicine, University of Belgrade;Department of Hemostasis, Blood Transfusion Institute of Serbia;Department of Hematology, University Hospital Medical Center Bezanijska Kosa;Faculty of Pharmacy, University of Belgrade;Center of Laboratory Medicine, Clinical Center of Vojvodina, Faculty of Medicine Novi Sad, University of Novi Sad

关键词: acute deep venous thrombosis;    recurrent thrombosis;    antithrombin deficiency;    type-II HBS;    COVID-19;   

DOI  :  10.1055/s-0041-1739129

来源: Thieme

【 摘 要 】

Coagulation dysfunction is a serious issue in patients with Coronavirus disease-19 (COVID-19). With regard to recently published studies, a high number of patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19 developed life-threatening thrombotic complications despite anticoagulation. We report a case of young woman with the type-II heparin-binding site (HBS) antithrombin (AT) deficiency (Budapest 3-homozygous), who developed acute deep vein thrombosis on two occasions due to COVID-19 infection in the course of stable anticoagulation with vitamin K antagonist. The first thrombotic event was observed during mild COVID-19 infection, while the second thrombotic event she developed 2 months after she was negative for severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). Our case highlights the complexity of the treatment in this particular type of thrombophilia and the need for precaution even in mild forms of viral infection. In the treatment of acute thrombosis, AT-deficient patients may benefit from the use of AT concentrate along with low-molecular weight heparin (LMWH), while in cases of type II-HBS, AT supplementation is mandatory.

【 授权许可】

Unknown